Can Kenvue (KVUE) Stock Reach $25?

Key Takeaways

• Price target in focus: Kenvue (KVUE) currently trades near $19.24, and the $25 level represents a psychologically significant round number that sits above the stock's all-time closing high of $24.34 set in May 2023.
• Strongest bullish factors: A portfolio of iconic consumer health brands including Tylenol, Neutrogena, and Band-Aid, a discounted cash flow fair value estimate near $25 from multiple independent models, and a healthy forward P/E (price-to-earnings) ratio of approximately 16.7 that leaves room for multiple expansion.
• Key obstacles: Revenue declined approximately 2% in fiscal 2025, organic sales contracted over 4% in some quarters, and the stock has underperformed the broader market by a wide margin over the past year.
• Critical levels to watch: Options market data identifies major support near $18 and resistance around $20, creating a corridor the stock must decisively break above before $25 becomes a realistic conversation.
• Bottom line: Reaching $25 would require a roughly 30% gain and is not supported by current Wall Street consensus targets, but it aligns with several independent fair value estimates and would still remain below the highest Street price objectives.

Why Investors Are Watching the $25 Level

The $25 price target has surfaced repeatedly across independent valuation models and select analyst reports. A widely followed discounted cash flow analysis on Simply Wall St estimates Kenvue's fair value at approximately $25.09 per share, while Jefferies maintained a $25 target on the stock even after trimming its estimate from $26 in mid-2025. The level also carries psychological weight: it sits just above Kenvue's all-time closing high of $24.34, meaning a move to $25 would represent uncharted territory and confirm a genuine breakout from the stock's post-IPO trading range.

Company Overview

Kenvue Inc. is the consumer health powerhouse spun off from Johnson & Johnson (JNJ) in May 2023. The company operates through three segments — Self Care, Skin Health and Beauty, and Essential Health — and owns some of the most recognized over-the-counter and personal care brands globally, including Tylenol, Listerine, Aveeno, Neutrogena, Johnson's Baby, and Band-Aid. With a market capitalization of roughly $37 billion and annual revenue approaching $15.3 billion, Kenvue is one of the largest pure-play consumer health companies in the world. Its products are sold across the United States, Europe, Asia-Pacific, and Latin America, providing geographic diversification that partially insulates results from regional economic weakness.

Current Market Position

As of late July 2026, KVUE trades near $19.24, placing it squarely in the middle of its 52-week range of $14.02 to $22.29. The stock has gained approximately 14% year-to-date, recovering from its October 2025 trough, but remains about 6% below where it stood one year ago. The company pays a quarterly dividend yielding roughly 4.3%, which has attracted income-oriented investors despite sluggish price performance. Institutional ownership stands above 94%, reflecting heavy accumulation by major asset managers including Vanguard, BlackRock, and State Street.

What Could Drive KVUE Toward $25

Several catalysts could help propel the stock toward the $25 mark. First, Kenvue's forward P/E of roughly 16.7 sits at a discount to peers in the personal products industry, and even a modest re-rating toward 20-22 times forward earnings — combined with expected EPS (earnings per share) growth toward $1.24 in fiscal 2026 — would mathematically support a price above $25. Second, the company's strategic portfolio review, including potential divestitures of smaller skin health brands, could sharpen management focus on higher-growth categories and unlock shareholder value. Third, Kenvue's gross margins above 58% demonstrate significant pricing power, and any stabilization or recovery in organic sales growth would likely shift sentiment materially. Finally, the company's aggressive share repurchase program and consistent dividend growth signal management confidence in long-term cash generation.

What Could Prevent the Move

The path to $25 faces genuine headwinds. Kenvue reported a 4% organic sales decline in the second quarter of 2025, driven by weaker consumption, trade inventory destocking, and elevated promotional activity. Revenue for the full year 2025 contracted roughly 2%, and the company guided toward continued low-single-digit declines. A trailing P/E above 22 also makes the stock appear expensive on current earnings, which limits the multiple-expansion argument until bottom-line growth reaccelerates. Additionally, input cost pressures and competition from private-label alternatives — particularly in categories like baby care and wound care — could compress margins. The broad analyst consensus remains a cautious Hold, with 12-month price targets clustered between $18 and $22, suggesting Wall Street is not yet convinced the stock deserves a premium valuation.

Analyst Opinions and Price Targets

Among 16 analysts covering KVUE, the average 12-month price target sits at approximately $19.58, representing only modest upside from current levels. The highest published target is $22 from firms including Jefferies, while the lowest stands at $18. Notably, the analyst consensus has drifted downward over the past year; one year ago, the average target was near $24.71. Still, several buy-side and independent valuation models paint a brighter picture. A DCF-based intrinsic value estimate of approximately $29.80 from Simply Wall St implies the stock trades at a significant discount to its theoretical worth, and a PJT Partners analysis prepared in connection with merger discussions valued Kenvue between $18 and $27.50 per share on a standalone basis — and as high as $45 when factoring potential synergies.

Technical Levels That Matter

From a technical standpoint, KVUE faces clearly defined boundaries. Options market open interest reveals a strong put wall at $18 providing downside support and a call wall at $20 acting as overhead resistance. The stock must first clear the $20-$22 zone — an area that aligns with the 52-week high and analyst consensus — before any credible attempt at $25 can materialize. The 200-day moving average, situated near $17.60, has been sloping upward and currently provides a bullish underlying trend structure. A sustained move above $20 on above-average volume would mark the first serious technical signal that higher levels are achievable.

AI Daily Buy/Sell Signals

For traders seeking a data-driven edge in evaluating opportunities like KVUE, Tickeron's AI Daily Buy/Sell Signals offer a powerful complement to traditional analysis. The platform uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating real-time Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven modeling. Rather than relying on static ratings, the system adapts as price action and fundamentals shift, helping traders identify emerging opportunities, monitor existing positions, and spot changing market trends with greater efficiency. Explore Tickeron's AI Daily Buy/Sell Signals to see how machine intelligence can enhance your market decision-making process.

Final Assessment

The question of whether Kenvue can reach $25 does not yield a simple yes or no. Based on current consensus analyst targets — which cluster between $18 and $22 — the $25 objective appears ambitious in the near term. However, independent valuation models consistently suggest the stock may be undervalued, with DCF-derived fair values landing squarely near or above $25. Achieving that level would likely require a combination of factors: organic sales growth returning to positive territory, successful execution of the ongoing strategic portfolio review, and a broader market willingness to re-rate consumer health stocks toward higher earnings multiples. Investors should monitor quarterly revenue trends, gross margin stability, and whether KVUE can decisively break above the $20 resistance zone. The $25 target is not imminent, but it is far from a fantasy — it sits squarely within the range of what fundamental analysis suggests the business may be worth under reasonable assumptions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.